Furthermore, MAD2 siRNA (siMAD2)-loaded on nanoparticles, has been presented as an attractive drug delivery platform for RNAi therapeutics against NSCLC 37. The gene discussed is MAD2L1; the disease is non-small cell lung carcinoma.